相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital
Hongli Luo et al.
BMC HEALTH SERVICES RESEARCH (2018)
Impact of an evaluation of the professional practices on the relevance of proton pump inhibitors prescriptions pertinence at the hospital
A. Daumas et al.
REVUE DE MEDECINE INTERNE (2018)
Low prevalence of osteoporosis treatment in patients with recurrent major osteoporotic fracture
J. Flais et al.
ARCHIVES OF OSTEOPOROSIS (2017)
UK clinical guideline for the prevention and treatment of osteoporosis
J. Compston et al.
ARCHIVES OF OSTEOPOROSIS (2017)
Osteoporosis Prevalence and Characteristics of Treated and Untreated Nursing Home Residents With Osteoporosis
Barbara J. Zarowitz et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2015)
Osteoporosis Screening, Prevention, and Management
Anna L. Golob et al.
MEDICAL CLINICS OF NORTH AMERICA (2015)
Osteoporosis in Menopause
Aliya Khan et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA (2014)
Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures
Chayanin Angthong et al.
ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA (2013)
The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis
Erik Landfeldt et al.
BONE (2012)
Prevalence, awareness, and treatment of osteoporosis among Korean women: The Fourth Korea National Health and Nutrition Examination Survey
Kyae Hyung Kim et al.
BONE (2012)
What do we know about atypical femoral fractures? Insights and enigmas
Maurice Audran et al.
JOINT BONE SPINE (2011)
Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate
Stuart H. Ralston et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
Ronald Emkey et al.
CLINICAL THERAPEUTICS (2009)
Osteoporosis: A still increasing prevalence
JY Reginster et al.
BONE (2006)
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use
B Cryer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study
JA Eisman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
分享论文
